Tumor Rebiopsy During Progression Under Immunotherapy for Patients With Lung Cancer

The objective of the study aims to collect tumor tissue at the moment of progression under Immune checkpoint inhibitors (ICI) in biological resources center in Ambroise Paré hospital, in order to insure later study on molecular mechanism involving the progression of NSCLC and SCLC under ICI.

The further analysis of research will be performed in the EA 4340 unity, Biomarkers and Clinical Trials in cancerology and onco-hematology, UVSQ, University of Paris-Saclay.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Lung Cancer Disease Attributes Disease Progression Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Pathologic Processes Pathological Conditions, Signs and Symptoms Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Service de Pneumologie et Oncologie thoracique, Hôpital Ambroise Paré, APHP

Boulogne-Billancourt, 92100, France

Location status: Recruiting

About this study

The study will consist of creation a tumor tissue bank, all sampling will be stored in the biological resources center of Ambroise Paré hospital.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosed NSCLC or SCLC;
Patient treated priorly by ICI and progressed under ICI;
Have provided written informed consent for the study;
Be >/= 18 years of age on day of signing informed consent.

Exclusion criteria

Patient under guardianship or curatorship;
Unable to provide written informed consent for the study;
Technical impossibility to carry out tissular rebiopsy under local anesthesia.

Treatment and study plan

Rebiopsy

Procedure

Biopsy will be carry out with flexible bronchoscopy as usual practice under local anesthesia: under endobronchial ultrasound, punction under CT scan or ultrasonography, percutaneous pleural puncturing.

Primary outcomes

Incidence of specific histomolecular resistance

Time frame: At the end of study, up to 2 years

Banking of tumor samples at progression with immune checkpoint inhibitor (ICI) in lung cancer, to evaluate the incidence of specific histomolecular resistance mechanisms to ICI by immunohistochemistry and molecular testing.

Study contacts

Contact information is provided by the study sponsor or research team.

Etienne Giroux Leprieur, MD, PhD

CONTACT

[email protected]

+33 1 49 09 58 02

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Acronym: REBIMMUNE

Important dates

Study start: 2020
Primary completion: 2027
Study completion: 2027
First posted: Mar 9, 2020
Registry last updated: Sep 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting